Fapon, a global leader in life sciences, introduced its innovative integrated diagnostics solutions and formed strategic partnerships at the 55th International Hospital and Medical Equipment Exhibition (MEDICA 2023). The event took place from November 13th to 16th, 2023 at the Düsseldorf Convention and Exhibition Center in Germany.
Industry sources added that at MEDICA, Fapon presented the market with the latest advances in its open, platform-based diagnostic ecosystem. With a consistent commitment of 22 years to the advancement of fundamental technologies of raw materials, reagents, and instruments, Fapon is committed to serving the global in-vitro diagnostics (IVD) sector and its partners through its integrated strategies for IVD core raw materials, reagent solutions, and open Support instrument platforms.
At MEDICA, Zhiqiang HE, President of Fapon Biotech, and Vidjongtius, President Director of PT Kalbe Farma Tbk, signed a Memorandum of Understanding (MoU) to deepen cooperation and promote IVD development in Indonesia. Founded in 1966, Kalbe Farma is one of the largest public pharmaceutical companies in Southeast Asia. This partnership marks another important milestone for Fapon to strengthen its presence in the Indonesian market, following its partnership with Halodoc, the largest telemedicine platform in Indonesia, in October this year.
Since the start of its global expansion, Fapon has been a consistent provider of diagnostic solutions to emerging markets such as India, Brazil, and beyond.
Industry sources also added that since launching the innovative open platform ecosystem, Fapon has been instrumental in placing more than 5,000 chemical luminescence immunoassay (CLIA) analyzers worldwide, engaging more than 250 ecosystem partners. At MEDICA, Fapon introduced numerous new raw materials and open instruments, demonstrating its enhanced capabilities in providing integrated diagnostic solutions.
Industry sources further added that Fapons Shine i8000/9000, a high-speed CLIA analyzer with a detection speed of 900 tests/hour, made its European debut. Dr. Sandeep K. Vashist, Senior Director of Global IVD Products of Fapon Biotech, introduced Fapon’s comprehensive product portfolio covering low, medium, and high-speed analyzers and highlighted the advantages of open instruments.
Industry sources further added that by presenting a range of raw materials such as influenza raw material (FLU), HIV P24 core material, and cardiac troponin I (cTnI) as well as blockers at MEDICA, Fapon aims to equip its partners with cutting-edge enabling technologies and superior products.
Fapon’s diagnostic solutions have received positive feedback and recognition from customers worldwide. A Southeast Asian customer said: “Fapon is our preferred choice for introducing new technologies and product lines in our country.” An Italian customer explained that “Fapon’s local services are fast and efficient, making them a reliable partner.” A South Asian customer who has worked with Fapon for over a decade has awarded the Fapon team a medal in recognition of their outstanding strategic partnership.
In line with the development philosophy of innovation-driven growth, Fapon’s business has expanded its presence to 68 countries and regions across six continents and won the trust and support of more than 2,500 customers worldwide. In the future, Fapon will continue to expand its technological advantages and expand its ecosystem. Working with partners, Fapon aims to build a diagnostic ecosystem, advance the development of global healthcare, and contribute to building a global healthcare ecosystem.
Are you searching online to find more news about biotechnology and life sciences? Then read these articles:
Neomorph appoints Bell Zhong as Chief Financial Officer
